Target trial emulation reveals lower five-year hepatocellular carcinoma risk among GLP-1 receptor agonist initiators with type 2 diabetes, indicating potential liver-protective benefits.
Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RA) may influence pathways involved in hepatocarcinogenesis, but evidence regarding their association with hepatocellular carcinoma (HCC) and mortality risk remains heterogeneous. We evaluated the association between GLP-1 RA initiation and HCC incidence compared with commonly used glucose-lowering medications, with secondary exploratory analyses of all-cause mortality following HCC diagnosis. Methods We emulated active-comparator, new-user target trials using Patient-Centered Clinical Research Network data from UT Southwestern Medical Center (PCORnet–UTSW; 2010–2025). Adults with T2D initiating GLP-1 RA were compared with initiators of metformin, insulin, sodium–glucose cotransporter-2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP4i), and sulfonylureas. The primary outcome was incident HCC; a secondary analysis evaluated all-cause mortality after HCC diagnosis. Five-year risks and risk differences under the intention-to-treat (ITT) approach were estimated using pooled logistic regression with inverse probability of treatment weighting. Per-protocol analyses accounted for treatment adherence using inverse probability of censoring weights. Results GLP-1 RA initiators had lower five-year HCC risk than comparator groups. Under ITT, risk differences were − 0.37% (95% CI − 0.59 to − 0.08) versus metformin, − 0.52% (95% CI − 0.74 to − 0.35) versus insulin, − 0.37% (95% CI − 0.70 to − 0.06) versus DPP4i, and − 0.39% (95% CI − 0.64 to − 0.13) versus sulfonylureas. Findings were stronger in per-protocol analyses and consistent across subgroups, sensitivity analyses and by individual GLP-1 RA agent. Mortality analyses were limited by small sample sizes but suggested a potential survival benefit. Conclusions GLP-1 RA initiation was associated with lower HCC risk versus several comparators. Mortality findings were inconclusive and exploratory, warranting confirmation in larger studies.
No takes yet. Share an insight, caveat, or question.
Hernández‐Pérez et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: